Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
This article was originally published in The Pink Sheet Daily
Executive Summary
The Contrave "complete response" letter could mean research in the category is sidelined now that all three of the current obesity drug candidates have been rejected.
You may also be interested in...
Orexigen Thinks Contrave On The Verge Of Approval, Again
The biotech once again faces an FDA approval decision for its bupropion/naltrexone obesity combo, after a long and costly cardiovascular outcomes trial has kept the drug off the market.
Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements
Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.
Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements
Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.